Source: Annual Congress 2006 - Recent advances in the treatment of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
K. A. Gunawardena, R. N. Wild, J. Kirkpatrick, S. D. Snape (Slough, Huntingdon, Cambridge, United Kingdom). NVA237, a once-daily anticholinergic, demonstrates sustained bronchodilation and is well tolerated in patients with reversible obstructive airways disease. Eur Respir J 2006; 28: Suppl. 50, 3050

Member's Comments

No comment yet.

Related content which might interest you: Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 639-644 Year: 2002 Bronchodilator responsiveness in patients with COPD Source: Eur Respir J 2008; 31: 742-750 Year: 2008 The effect of tiotropium on exacerbations and airflow in patients with COPD Source: Eur Respir J 2006; 27: 547-555 Year: 2006 A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease Source: Eur Respir J 2002; 19: 217-224 Year: 2002 Oral or inhaled corticosteroids for patients with chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=281 Year: 2006 Formoterol demonstrates bronchodilator efficacy in patients with reversible or poorly reversible chronic obstructive pulmonary disease (COPD), regardless of concomitant corticosteroid use Source: Eur Respir J 2001; 18: Suppl. 33, 177s Year: 2001 Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: 86-94 Year: 2004 Evaluation of bronchodilator responses in patients with "irreversible" emphysema Source: Eur Respir J 2001; 18: 914-920 Year: 2001 Rapid onset bronchodilation with formoterol or salbutamol in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 514s Year: 2001 What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Source: Eur Respir J 2002; 19: 928-935 Year: 2002 Roflumilast with long-acting ?2-agonists for COPD: influence of exacerbation history Source: Eur Respir J 2011; 38: 553-560 Year: 2011 Tiotropium as essential maintenance therapy in COPD Source: Eur Respir Rev 2006; 15: 51-57 Year: 2006 Treatment with corticosteroids and yearly decline of forced expiratory flow (FEV1) in patients with severe chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Respiratory structure and function Year: 2008 Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Source: Eur Respir J 2003; 21: 74-81 Year: 2003 Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD Source: Eur Respir J 2004; 23: 832-840 Year: 2004 The role of concomitant respiratory diseases on the rate of decline in FEV1 among adult asthmatics Source: Eur Respir J 2003; 21: 95-10 Year: 2003 Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial Source: Eur Respir J 2002; 19: 936-943 Year: 2002 FEV1 is not sufficient for assessing bronchodilator reversibility in chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 121s Year: 2004 Exercise and dyspnoea in COPD Source: Eur Respir Rev 2006; 15: 72-79 Year: 2006